Tennessee’s Kratom Ban Is Here: What Could It Mean for Georgia and Other States?

Tennessee’s kratom ban took effect July 1, 2026, making it the latest state to prohibit a substance that Georgia still allows adults to buy legally. For daily users and their families, that contrast raises an urgent question: does Georgia’s regulated status mean kratom use is safe, and could a ban come here next? This article breaks down what the Tennessee ban means, how Georgia’s law compares, and what the science says about knowing when use has crossed into dependence.Tennessee’s Kratom Ban and What It Changes

Tennessee’s prohibition, known as Matthew Davenport’s Law, is one of the most closely watched kratom ban 2026 developments in the country. It puts Tennessee alongside Alabama and Arkansas as Southern states that have moved from tolerance to outright prohibition. For Georgia residents, the practical effect is immediate: driving across the state line with kratom products is now a legal risk, and anyone dependent on daily use faces a supply disruption the moment they travel north.

The ban also sends a signal to other state legislatures. When a neighboring state acts, it creates political pressure and public debate that can shift the conversation quickly. Georgia is not immune to that pressure.

Why Tennessee Acted

Tennessee named its law after Matthew Davenport, which suggests the ban was driven at least partly by a specific harm case rather than abstract policy. 

U.S. law does not provide one uniform legal status for every kratom product. Federal controlled-substance law, federal food and drug law, and state law must be considered separately. Some states broadly prohibit kratom, while others permit regulated sales or prohibit only certain products. For example, Alabama, Connecticut, and Louisiana currently prohibit kratom broadly, while Rhode Island permits licensed sales of compliant products.

Below are detailed explanations following the legal status of every kratom product:

Whole Kratom Leaves

Not federally scheduled as a controlled substance as of August 3, 2026. However, possession or sale is prohibited in some states, and FDA does not consider kratom lawfully marketable as a dietary supplement, conventional food ingredient, or approved drug.

Crushed Kratom Leaf

Not federally scheduled as a controlled substance as of August 3, 2026. It remains subject to FDA restrictions on food and supplement marketing and may be prohibited under state law.

Plain Kratom Powder

Not federally scheduled as a controlled substance as of August 3, 2026. Nevertheless, FDA states that kratom products cannot lawfully be marketed as dietary supplements or added to conventional foods.

Red, Green, and White Kratom

Not separate legal categories under the federal sources reviewed. These names are product or marketing classifications; legal status depends on the actual ingredients, alkaloid levels, product claims, and applicable state law.

Kratom Capsules

Not federally prohibited solely because they are capsules. Plain-leaf capsules are not federally scheduled, but FDA does not recognize kratom as a lawful dietary-supplement ingredient, and some states prohibit products containing kratom alkaloids.

Kratom Tea

Not federally scheduled solely because it is tea. Commercially marketed kratom tea is still subject to FDA’s position that kratom cannot lawfully be added to or marketed as conventional food.

Kratom Extract Powder

Not federally scheduled as a product category as of August 3, 2026. However, FDA has specifically stated that kratom extract is not an authorized food additive and has treated foods containing it as adulterated. Extracts containing elevated 7-OH may also fall within the DEA’s pending scheduling action.

Liquid Kratom Extracts and Tinctures

Not federally scheduled merely because they are liquid extracts. FDA food, supplement, and drug restrictions still apply, and products containing enhanced 7-OH face additional enforcement and possible federal scheduling.

Kratom Shots

Not automatically federally controlled based on format alone. Ordinary kratom shots remain unlawfully marketed when sold as conventional foods or dietary supplements, while shots containing added or enhanced 7-OH are explicitly targeted by FDA enforcement.

Kratom Gummies and Edibles

Not automatically federally controlled based on format alone. FDA considers kratom unlawful as a food or dietary-supplement ingredient, and gummies or edibles containing added or enhanced 7-OH are specifically considered unlawfully marketed products.

Enhanced or Fortified Kratom Products

Not necessarily federally controlled yet, but not lawfully marketed as foods or dietary supplements. Products with elevated 7-OH may meet the threshold covered by DEA’s pending temporary Schedule I action.

Mitragynine Isolate Products

Not included in the DEA’s July 2026 scheduling notices merely because they contain mitragynine. However, no FDA-approved prescription or over-the-counter drug containing mitragynine exists, and individual states may classify mitragynine as a controlled substance.

Concentrated 7-Hydroxymitragynine Products

Not yet federally Schedule I as of August 3, 2026, but not lawfully marketed as foods, dietary supplements, or approved drugs. DEA has announced its intent to temporarily schedule 7-OH above a specified threshold, with an order permitted on or after August 5, 2026.

The proposed federal threshold covers botanical material containing more than 0.050% 7-OH by dry weight and certain processed or synthetic products containing more than 0.050% 7-OH or more than 1 milligram of 7-OH in the article. These thresholds are proposed and are not yet effective as of August 3, 2026.

Mitragynine Pseudoindoxyl

Not yet federally Schedule I as of August 3, 2026. DEA has issued a notice of intent to place mitragynine pseudoindoxyl temporarily in Schedule I, with the order expected no earlier than August 5, 2026.

MGM-15

Not yet federally Schedule I as of August 3, 2026. DEA has issued a notice of intent to temporarily schedule MGM-15, also identified as dihydro-7-hydroxymitragynine.

MGM-16

Not yet federally Schedule I as of August 3, 2026. DEA has issued a notice of intent to temporarily schedule MGM-16, described as a 9-fluoro derivative of 7-hydroxymitragynine.

Kratom Products Marketed as Medical Treatments

Not lawfully marketed as approved treatments. FDA has approved no prescription or over-the-counter drug containing kratom, mitragynine, or 7-OH. Products claiming to diagnose, treat, cure, or prevent conditions may be treated as unapproved drugs.

That broad approach differs from the federal direction, which has increasingly focused on concentrated 7-OH products rather than natural leaf. In July 2026, the DEA announced intent to temporarily place 7-OH products into Schedule I following FDA recommendations, citing misuse, dependence, overdose, and opioid-like health risks, while making a distinction that botanical kratom below a specified natural threshold was not covered.

Georgia Kratom Laws: Where Things Stand Now

Georgia currently takes a regulate-rather-than-ban approach. Under HB181, signed by Governor Brian Kemp in May 2024 and effective January 1, 2025, Georgia legally defined kratom, raised the purchase age to 21, imposed labeling requirements, restricted products to behind-counter display, and banned kratom in vaping-device formats. Retailers and processors that violate the rules face penalties.

That framework resembles the Kratom Consumer Protection Act model used in several other states: preserve adult access while reducing risk through age gates, purity standards, and labeling rules. Georgia is not alone in this approach, but it is now a regulated-access state bordered by states with stricter positions.

A Possible Shift on the Horizon

Georgia’s regulated status is not guaranteed to last. HB968 was introduced in 2026 and would reportedly reclassify mitragynine and 7-OH as Schedule I substances if enacted. Secondary sources indicate it had not passed as of mid-2026, and BillTrack50 lists a related processor-registration bill, HB757, as dead as of April 2, 2026. Still, the legislative activity shows that Georgia’s current framework is being actively contested.

Daily users who rely on Georgia’s regulated market should not wait for a law change to make a health plan. A sudden ban can disrupt supply overnight and intensify withdrawal risk for anyone who has developed physical dependence.

Kratom Laws by State: A Patchwork That Keeps Shifting

The national picture on kratom laws by state is genuinely confusing, and it changes year to year. Here is a simplified snapshot based on the most current sources available:

• Alabama: banned
• Arkansas: banned
• Tennessee: banned as of July 1, 2026
• Georgia: regulated, adults 21 and older, with labeling and display requirements
• Several other states: have adopted Kratom Consumer Protection Act frameworks with age restrictions and labeling
• Federal level: natural leaf kratom is not federally controlled, but concentrated 7-OH products face new scheduling action

The full 2026 state map shows a country divided between prohibition states, regulated-access states, and states with no specific kratom law at all. That patchwork creates real problems for daily users who travel, move, or order products online.

What 7-OH Kratom Laws Mean Separately

The 7-OH kratom laws picture is even more fragmented. Concentrated 7-hydroxymitragynine products, sold as gummies, tablets, drink shots, and “enhanced” capsules, are increasingly treated as a separate legal category from plain leaf kratom. The DEA’s July 2026 action targets elevated or chemically manipulated 7-OH, not botanical kratom below natural thresholds. Several states have moved to restrict or ban 7-OH products specifically, and state-by-state 7-OH bans are being tracked separately from general kratom prohibition.

For Georgia users, this matters because a product labeled “kratom” at a gas station or vape shop may actually be a concentrated 7-OH product with a very different risk profile. The label does not always tell the full story.

The Future of Kratom Regulation: What the Trends Suggest

The future of kratom regulation is moving in two directions at once, and both matter for Georgia.

The first direction is toward tighter control of concentrated products. Federal agencies are drawing a line between natural leaf and chemically elevated 7-OH. The American Kratom Association, which advocates for natural kratom access, has itself warned consumers that enhanced 7-OH products are not real kratom and pose significant safety risks. That unusual alignment between regulators and industry advocates suggests the concentrated-product crackdown has real momentum.

The second direction is state-level prohibition of all kratom, regardless of form. Tennessee’s ban is the most recent example. Alabama and Arkansas have held their bans for years. Each new state prohibition creates a template and a political argument for the next one.

Georgia sits between these two approaches. Its current law follows a regulated-access model, restricting kratom sales to adults aged 21 and older and imposing product, labeling, and retail-display requirements. However, Georgia House Bill 968 proposed classifying mitragynine and 7-hydroxymitragynine as Schedule I controlled substances and repealing the state’s existing kratom regulatory framework. Although the bill did not become law during the 2025–2026 legislative session, its introduction and committee consideration demonstrate that broader prohibition remains part of Georgia’s legislative debate.

What Regulation Does Not Tell You About Dependence

One of the most important things to understand about Georgia’s current law is what it does not do. Regulation answers whether a product can be legally purchased. It does not answer whether a person can stop using it without withdrawal, craving, or functional harm.

Physical dependence can develop with daily use of any substance that acts on opioid receptors, including kratom. The HHS guide for clinicians on opioid dosage reduction notes that physical dependence can occur with daily around-the-clock use for more than a few days, meaning the body adapts and withdrawal may follow if use abruptly stops. That principle applies to kratom, especially concentrated 7-OH products.

A Georgia adult can be legally buying a compliant product and still be physically dependent on it. Legality and dependence are separate questions.

Recognizing Dependence: The Signs That Matter

The clearest sign that daily kratom use has become a problem is not the total grams consumed. It is the shift from voluntary benefit-seeking to withdrawal-avoidance and loss of control.

A peer-reviewed review in “The American Journal on Addictions” describes the pattern plainly: after a while, the person is no longer getting high. They just need the substance so they are not sick. That quote, drawn from opioid withdrawal research, maps directly onto what many daily kratom users describe.

Physical warning signs include waking up with runny nose, sweating, yawning, muscle aches, loose stools, or anxiety that resolves after the first dose. 

Behavioral warning signs include dose escalation, switching from leaf powder to extracts or 7-OH products, failed attempts to cut back, hiding use, and continuing despite relationship, work, or health problems.

The Palliative Care Network of Wisconsin describes opioid use disorder as characterized by impaired control, continued use despite harm, and craving. That framework applies to kratom patterns that behave similarly, especially with concentrated 7-OH products.

Why Abrupt Stopping Can Backfire

If you recognize dependence in yourself or someone you care about, throwing away the supply is not always the safest first step. HHS guidance warns that rapid discontinuation in physically dependent individuals can cause acute withdrawal, worsened pain, serious psychological distress, and in some cases suicidal thoughts. A clinical review of opioid tapering approaches supports slow, planned reduction with supportive interventions rather than sudden deprivation.

For anyone using concentrated 7-OH products, using high doses daily, or mixing kratom with alcohol, benzodiazepines, or other sedatives, medical support before stopping is especially important.

What Georgia Residents Should Do Now

The Tennessee ban is a useful planning signal even for people who live in Georgia and have no plans to travel. It shows that the legal environment can change quickly and that daily dependent users are the most vulnerable when it does.

Here are the most practical steps:

• Be honest about your product type. Plain leaf powder carries different risks than concentrated 7-OH tablets, shots, or gummies.
• Track your dose and timing. If you feel sick before the first dose of the day, that is a dependence signal worth taking seriously.
• Tell your doctor what you actually use. Clinicians cannot assess risk without knowing the product, dose, and frequency.
• Do not mix kratom or 7-OH with alcohol, benzodiazepines, opioids, or sleep medications. The combination raises respiratory risk significantly.
• Make a plan before the law changes, not after. A sudden ban is a much harder moment to begin a taper or seek support.

If you or someone you love is struggling to stop, experiencing withdrawal, or using concentrated 7-OH products daily, professional support is available and can make the process safer and more sustainable.

If you are ready to talk with someone about kratom dependence or withdrawal, the team at Thoroughbred Wellness and Recovery in Marietta, Georgia offers medical detox support for opioid-like dependence and co-occurring mental health concerns, with care available around the clock.